---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-166208"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-06-02T23:59:59+00:00"
generated_at: "2026-06-25T05:05:12.991478+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan

## Summary
- Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.
- Ratification of Mayer Hoffman McCann as independent auditor for FY2022: 8,107,698 for, 157,062 against, 57,490 abstentions.
- Increase to 2021 Equity Incentive Plan approved: 2,826,803 for, 2,106,190 against, 15,587 abstentions, 3,373,670 broker non-votes.

## SEC filing metadata
- accession: 0001193125-22-166208
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/0001193125-22-166208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/d348649d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-166208
- JSON: https://secwatch.observer/filing/0001193125-22-166208.json
- Plain text: https://secwatch.observer/filing/0001193125-22-166208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.